Use of ECG Restitution (Beat-to-Beat QT-TQ Interval Analysis) to Assess Arrhythmogenic Risk of QTc Prolongation with Guanfacine

Background Guanfacine (Intuniv) is a centrally active alpha‐2A adrenergic agonist for the new indication of attention‐deficit/hyperactivity disorder. QTc (QTcF and QTcNi) was prolonged at both therapeutic (4 mg) and supratherapeutic (8 mg) doses of a thorough QT study even though guanfacine has had...

Full description

Saved in:
Bibliographic Details
Published inAnnals of noninvasive electrocardiology Vol. 19; no. 6; pp. 582 - 594
Main Authors Fossa, Anthony A., Zhou, Meijian, Robinson, Antoine, Purkayastha, Jaideep, Martin, Patrick
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.11.2014
John Wiley & Sons, Inc
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Guanfacine (Intuniv) is a centrally active alpha‐2A adrenergic agonist for the new indication of attention‐deficit/hyperactivity disorder. QTc (QTcF and QTcNi) was prolonged at both therapeutic (4 mg) and supratherapeutic (8 mg) doses of a thorough QT study even though guanfacine has had a safe clinical history of over 3 million prescriptions for the treatment of hypertension. In an attempt to understand this disparity, retrospective evaluation of the continuous ECG data utilized dynamic beat‐to‐beat and ECG restitution analyses was performed. Methods Sixty healthy subjects using 24‐hour Holters were examined in a 3‐arm, placebo‐ and positive‐controlled, double‐blind crossover study for effects on beat‐to‐beat QT, TQ, and RR intervals. Results ECG restitution analyses indicated that, at all time points, a disproportionate effect to increase the TQ interval (rest) occurred more in relationship to each QT interval lengthening resulting in a placebo‐adjusted reduced QT/TQ ratio of 21% after 4 mg and 31% after 8 mg (both antiarrhythmic responses). Additionally, the percentage of time and magnitude of stress on the heart, as measured by the upper limits of the QT/TQ ratio, were reduced with guanfacine by 22% to 24%. In contrast to guanfacine, moxifloxacin did not show a significant improvement in any restitution parameters but reflected a trend toward proarrhythmia with an increase in the QT/TQ ratio of up to 11%. Conclusion These results indicate that guanfacine causes a stabilizing effect on cardiac restitution that helps reconcile the clinical evidence for a lack of arrhythmia liability despite apparent increases in typical QT/QTc prolongation measures.
Bibliography:Shire Development LLC
ArticleID:ANEC12202
istex:A2C06DF45C21E4BE5E7C6E40334B7B72B6CFBD43
ark:/67375/WNG-HCZTT2N5-R
Disclosures: Anthony Fossa and Meijian Zhou are former and current employees of iCardiac Technologies, respectively, and do not hold stock and or stock options at iCardiac. Antoine Robinson is a former employee of Shire, Jaideep Purkayastha and Patrick Martin are employees of Shire, and hold stock and/or stock options at Shire.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1082-720X
1542-474X
1542-474X
DOI:10.1111/anec.12202